Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Phase 2 Unknown 30 enrolled Hebei Medical University

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the efficacy and safety of intraperitoneal and intravenous nab-paclitaxel plus Camrelizumab and S-1 conversion therapy for gastric cancer with positive exfoliative cancer cells.

Timeline

Start: 2022-06-30
Primary completion: 2023-06-30
Completion: 2025-06-30

Publications

Lv J, Wu J, Wu H, Ding P, Guo H, Yang P, Tian Y, Liu Y, Zhao Q. Study protocol of a phase II clinical trial evaluating the efficacy of neoadjuvant intraperitoneal and systemic albumin-bound paclitaxel combined with camrelizumab and S-1 in the treatment of patients with exfoliative cell-positive gastric cancer. Front Oncol. 2023 Sep 29;13:1201928. doi: 10.3389/fonc.2023.1201928. eCollection 2023.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Camrelizumab	Monoclonal antibody	200 mg	Intravenous
Subject	Nab-paclitaxel	Small molecule	80 mg/m2	Other
Subject	Nab-paclitaxel	Small molecule	180 mg/m2	Other
Subject	S-1	Small molecule	40 mg	—
Subject	S-1	Small molecule	50 mg	—
Subject	S-1	Small molecule	60 mg	—

Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Summary

Timeline

Publications

Drugs

Indications